Intoplicine dimesylate is primarily investigated for its potential in cancer therapy due to its ability to inhibit topoisomerase II, an enzyme critical for DNA replication and cell division. This mechanism makes it a candidate for treating various malignancies, particularly in cases where tumors are resistant to other treatments. Research has explored its efficacy in both solid tumors and hematologic cancers, with studies focusing on its impact on cell cycle arrest and apoptosis. Additionally, its role in combination therapies is being examined to enhance the overall effectiveness of existing chemotherapeutic regimens. Ongoing clinical trials aim to determine optimal dosing, safety profiles, and specific cancer types that may benefit most from its application.